Live
- Dairy Science students visited the Milk cooling plant
- Moody feels Pant ahead in keepers’ race for T20 WC squad; Srikkanth picks Rahul over Samson as reserve keeper
- Thanking voters for extending 'unparalleled support' to NDA, PM Modi says second phase 'too good'
- Natural Relief for Menstrual Cramps: Beetroot Juice Recipe
- Asha Worker died in a road accident
- Akshaya Tritiya 2024 Auspicious Hindu Festival on May 10th
- Celebrating World Veterinary Day 2024: Safeguarding Your Pet’s Vision with Expert Tips
- NSG joins CBI in searching residence of Sheikh Shahjahan’s relative
- Maharashtra: Peeved state unit Congress Working President quits 2024 LS polls campaign
- Archery World Cup: Deepika storms into individual semis; Compound Mixed Team in final
Dr Reddy’s launches anti-viral drug in US
Dr Reddy’s Launches Anti-Viral Drug in US. City-based Dr Reddy’s Laboratories launched antiviral drug Valganciclovir Tablets USP 450 mg in the US market following approval from the health regulator United States Food & Drug Administration (USFDA) on Monday.
.jpg)
Hyderabad: City-based Dr Reddy’s Laboratories launched antiviral drug Valganciclovir Tablets USP 450 mg in the US market following approval from the health regulator United States Food & Drug Administration (USFDA) on Monday.
The new drug is a therapeutic equivalent generic version of Valcyte (Valganciclovir) tablets sold by Roche Holdings AG, a Swiss global healthcare company.
It is used for the treatment of viral infections caused by cytomegalovirus.
The Valcyte tablets brand had US sales of approximately $440 million MAT for the most recent twelve months ending in October 2014, Dr Reddy’s said in a release, citing IMS Health data. Dr Reddy’s Valganciclovir tablets, USP in 450 mg are available in bottle counts of 60.
Dr Reddy’s rolled out the drug in US market after Ranbaxy Laboratories lost the six-month exclusivity rights on it following the USFDA’s decision to revoke the tentative approvals granted to the Gurgaon-based pharmaceutical major.
